Almedika - Company finances
|
EUR
|
2023
From: 2023-02-08
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 307,571 | 942,280 | 506,318 |
| Profit before tax | - | - | - |
| Net profit | 141,218 | 196,735 | 6,532 |
| Equity | 143,718 | 222,805 | 146,985 |
| Liabilities | 50,318 | 112,335 | 120,168 |
| Non-current assets | 44,690 | 124,865 | 107,027 |
| Current assets | 147,856 | 207,180 | 156,969 |
| Total assets | 192,546 | 332,045 | 263,996 |
|
Taxes paid
|
|||
| STI taxes | 17,835 | 172,233 | 106,891 |
| Social insurance contributions | - | 11,384 | 11,273 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +206.4% | -46.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 73.3% | 59.2% | 2.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 98.3% | 88.3% | 4.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 45.9% | 20.9% | 1.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.5 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 140,971 | 235,570 | 126,580 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Almedika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-08-19 | 2024-09-08 | 0.01 |
| 2024-07-24 | 2024-08-01 | 0.01 |
Almedika - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-01-29 | 2026-02-16 | 0.98 |
| 2026-01-10 | 2026-01-13 | 253.0 |
| 2025-06-19 | 2025-07-20 | 1.65 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Almedika, UAB (code 306243147) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €506.3K and net profit of €6.5K, resulting in a profit margin of 1.3%. Revenue decreased by 46.3% year on year in 2025, after a much stronger 2024, when sales reached €942.3K and net profit was €196.7K. In 2023, for a 326-day period, revenue was €307.6K and net profit €141.2K, showing that the company experienced a significant expansion in 2024 followed by a weaker 2025 result. As of 2025, total assets stood at €264.0K, equity at €147.0K, and liabilities at €120.2K. The equity ratio was 55.7% and debt-to-equity 0.82, indicating a balanced capital structure. Asset turnover was 1.92x, ROE 4.4%, and ROA 2.5%. Revenue per employee was €126.6K, while profit per employee was €1.6K.